Rezolute (NASDAQ:RZLT) Share Price Breaks Above 200 Day Moving Average - Here's What Happened

Rezolute logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rezolute shares moved above their 200-day moving average of $3.89, reaching $4.13 before last trading at $4.01; the stock was up 3.4%.
  • Analyst views were mixed, but the consensus rating was “Moderate Buy” with an average price target of $11.22; 12 analysts rated the stock Buy and two rated it Sell.
  • Rezolute reported a quarterly loss of $0.20 per share, missing the consensus estimate of a $0.15 loss by $0.05.
  • MarketBeat previews top five stocks to own in December.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.89 and traded as high as $4.13. Rezolute shares last traded at $4.01, with a volume of 919,233 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Zacks Research cut shares of Rezolute from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 13th. HC Wainwright increased their price objective on shares of Rezolute from $5.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, September 25th. Lake Street Capital raised their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Citizens Jmp raised their target price on shares of Rezolute from $11.00 to $15.00 and gave the stock a "market outperform" rating in a research note on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rezolute in a report on Thursday, October 15th. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Rezolute presently has an average rating of "Moderate Buy" and an average price target of $11.22.

Check Out Our Latest Analysis on RZLT

Rezolute Stock Up 3.4%

The company has a market cap of $387.89 million, a P/E ratio of -5.28 and a beta of 0.65. The stock has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $3.89.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). Equities analysts anticipate that Rezolute, Inc. will post -0.63 EPS for the current year.

Hedge Funds Weigh In On Rezolute

A number of hedge funds have recently bought and sold shares of RZLT. Jennison Associates LLC acquired a new position in Rezolute in the 1st quarter valued at $10,489,000. Siren L.L.C. bought a new stake in shares of Rezolute during the 1st quarter valued at $10,151,000. Dimensional Fund Advisors LP grew its holdings in shares of Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock worth $1,617,000 after purchasing an additional 388,346 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Rezolute during the 2nd quarter worth $1,104,000. Finally, Sei Investments Co. increased its position in shares of Rezolute by 286.8% in the first quarter. Sei Investments Co. now owns 146,576 shares of the company's stock worth $447,000 after purchasing an additional 108,679 shares during the period. 82.97% of the stock is owned by institutional investors.

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company's lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rezolute Right Now?

Before you consider Rezolute, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.

While Rezolute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines